Literature DB >> 27658735

Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma.

Ritu Gupta1, Lalit Kumar2, Meetu Dahiya1, Nitin Mathur1, P Harish2, Atul Sharma2, Om Dutt Sharma1, Varun Shekhar3.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27658735     DOI: 10.1080/10428194.2016.1228930

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  4 in total

1.  Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.

Authors:  Chutima Kunacheewa; Hans C Lee; Krina Patel; Sheeba Thomas; Behrang Amini; Samer Srour; Qaiser Bashir; Yago Nieto; Muzzaffar H Qazilbash; Donna M Weber; Lei Feng; Robert Z Orlowski; Pei Lin; Elisabet E Manasanch
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-01-15

2.  Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT.

Authors:  Qian Sun; Xiaozhe Li; Jingli Gu; Beihui Huang; Junru Liu; Meilan Chen; Juan Li
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

3.  Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance.

Authors:  Gang Wang; Fang-Ying Ning; Jia-Heng Wang; Hai-Meng Yan; Hong-Wei Kong; Yu-Ting Zhang; Qiang Shen
Journal:  World J Clin Cases       Date:  2019-12-26       Impact factor: 1.337

4.  [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].

Authors:  S H Deng; Y Xu; W W Sui; H J Wang; Z J Li; T Y Wang; W Liu; W Y Huang; R Lyu; J Li; M W Fu; D H Zou; G An; L G Qiu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.